Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
Ronald van Vollenhoven(Amsterdam University Medical Centers), David Gordon(Universidade Federal de Ouro Preto), James Groark(Pfizer (United States)), Tania Gonzalez‐Rivera, Damon Bass(GlaxoSmithKline (United States)), Milena Kurtinecz(Bayer (United States)), Richard Furie(Hofstra University), William Eastman(Eli Lilly (United States)), Bonnie Pobiner(Research Triangle Park Foundation), Norma Lynn Fox, William Stohl(University of Southern California)
Cited by 17
Related Papers
<i>Consed:</i> A Graphical Tool for Sequence Finishing
|Genome Research|1998|3.3k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
|New England Journal of Medicine|2005|2k
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
|New England Journal of Medicine|2018|1.6k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k